Abionyx Pharma: successful capital increase

(CercleFinance.com) - On Monday, biotech company Abionyx Pharma announced that it had successfully completed its capital increase of around 3.
4 million euros.

The company announced that it had fully subscribed to 2.47 million new ordinary shares, each with a share purchase warrant (ABSA), at a price of 1.37 euros.

The aim of the fund-raising is to strengthen the company's cash position as part of the development of its sepsis program, by extending its financial visibility until the end of 2025.

In terms of dilution, a shareholder who held 1% of Abionyx's capital before the operation will see his stake reduced to 0.93% of the capital, or 0.87% if all the warrants are exercised.

Copyright (c) 2024 CercleFinance.com. All rights reserved.